Price$2.71-1.54 (-36.35%)
2026-03-042026-06-05
News · 26 weeks71-88%
2025-12-142026-06-07
Mix3590d
- Insider11(31%)
- SEC Filings9(26%)
- Other8(23%)
- Offering4(11%)
- Analyst2(6%)
- Earnings1(3%)
Latest news
25 items- PRPemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026"Best of EASL" oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple cardiometabo
- PRAltimmune to Participate in Upcoming Investor ConferencesGAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare ConferenceThursday, June 4, 2026Fireside chat at 12:50 p.m. ETNew York, NY Goldman Sachs 47th Annual Global Healthcare Conference Wednesday, June 10, 2026Fireside chat at 8:00 a.m. ETMiami Beach, FL A webcast of the fireside chats will be available via the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical co
- PRNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tes
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)
- SECSEC Form S-8 filed by Altimmune Inc.S-8 - Altimmune, Inc. (0001326190) (Filer)
- SECSEC Form 10-Q filed by Altimmune Inc.10-Q - Altimmune, Inc. (0001326190) (Filer)
- PRNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE:S
- SECAltimmune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Altimmune, Inc. (0001326190) (Filer)
- PRAltimmune Announces First Quarter 2026 Financial Results and Business UpdateInitiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. "We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune," said Jerry Durso, President and Chief Executive Officer of Altimmune. "As a result of the
- SECSEC Form SCHEDULE 13G filed by Altimmune Inc.SCHEDULE 13G - Altimmune, Inc. (0001326190) (Subject)
- PRAltimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on May 13 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the
- SECSEC Form SCHEDULE 13G filed by Altimmune Inc.SCHEDULE 13G - Altimmune, Inc. (0001326190) (Subject)
- INSIDERSEC Form 4 filed by Director Lawver Teri L4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Director Sohn Catherine A.4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Director Jorkasky Diane4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Director Schafer Klaus4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Director Pisano Wayne4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Director Hodges Philip4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Director Gill John4 - Altimmune, Inc. (0001326190) (Issuer)
- INSIDERSEC Form 4 filed by Director Sayare Mitchel4 - Altimmune, Inc. (0001326190) (Issuer)
- PRAltimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with participation from TCGX, Viking Global Investors, RA Capital Management, and other new and existing investors GAITHERSBURG, Md., April 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the closing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and 64,250,000 accompanying common stock warra
- SECSEC Form 8-K filed by Altimmune Inc.8-K - Altimmune, Inc. (0001326190) (Filer)
- ANALYSTAltimmune upgraded by Goldman with a new price targetGoldman upgraded Altimmune from Sell to Neutral and set a new price target of $2.50
- SECSEC Form 424B5 filed by Altimmune Inc.424B5 - Altimmune, Inc. (0001326190) (Filer)
- PRAltimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 64,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and accompanying common stock warrants to purchase an aggregat
ALT FAQ
6 questionsWhat does Altimmune Inc. do?
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant...Where does ALT stock trade?
Altimmune Inc. (ALT) is listed on NASDAQ.What sector and industry is ALT in?
Altimmune Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ALT?
Altimmune Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $250.00 price target on 2026-04-24.What companies are similar to ALT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALT side-by-side with any of them on Quantisnow.How can I track ALT on Quantisnow?
Quantisnow aggregates Altimmune Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALT to receive live email and push alerts on every new disclosure.